Abbott Laboratories (ABT) stock
ABT · Abbott Laboratories · NYSE
What is the latest news on ABT stock?
ABT fell 0.75% to $103.18 on Nov 20, 2026. No ABT story in the last two days; the most recent is below.
Abbott's Encantor system includes software-guided deployment technology designed to help optimize valve expansion to the patient's unique anatomy, supporting precise implantation and consistent valve performanceEncantor early feasibility study data will be presented at PCR London Valves 2026ABBOTT PARK, Ill., Nov. 19, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, announced today it has initiated the VOYAGER CE clinical trial evaluating the safety and efficacy of its investigational Encantor™ transcatheter aortic valve implantation (TAVI) software-guided balloon-expandable system for treating symptomatic severe aortic stenosis. The first enrollment in the VOYAGER CE st
All ABT newsWho owns the most ABT stock?
BlackRock, Inc. was the largest reported holder of ABT at the end of Q2 2026, with 152,563,476 shares worth $13.8 billion. Next came Vanguard Capital Management LLC ($10.3 billion) and State Street Corp ($7.3 billion). In all, 2,965 institutions reported $125.5 billion of ABT in their 13F filings.
All ABT fund holdersAre insiders buying or selling ABT?
Insiders are selling. In the last 90 days 3 insiders sold $46.6 million of ABT in trades reported on Form 4. The latest: Mary K Moreland sold $406K, reported on Nov 6, 2026.
ABT insider tradesFinancial highlights
Full financials- Revenue, TTM
- $48.23B
- Revenue growth
- +10.0%
- Net income, TTM
- $4.70B
- Net margin
- 9.7%
- Free cash flow, TTM
- $6.76B
- Cash
- $4.05B
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Latest news
25 items- PRAbbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosisAbbott's Encantor system includes software-guided deployment technology designed to help optimize valve expansion to the patient's unique anatomy, supporting precise implantation and consistent valve performanceEncantor early feasibility study data will be presented at PCR London Valves 2026ABBOTT PARK, Ill., Nov. 19, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, announced today it has initiated the VOYAGER CE clinical trial evaluating the safety and efficacy of its investigational Encantor™ transcatheter aortic valve implantation (TAVI) software-guided balloon-expandable system for treating symptomatic severe aortic stenosis. The first enrollment in the VOYAGER CE st
- ANALYSTAbbott Labs upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Abbott Labs from Market Perform to Outperform and set a new price target of $124.00
- SECAbbott Laboratories filed SEC Form 8-K: Leadership Update8-K - ABBOTT LABORATORIES (ABT) (CIK 0000001800)
- PRNew Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness SeasonNew survey reveals 72 per cent of Canadians say knowing whether they had the flu or COVID-19 would help guide next stepsi Respiratory viruses often present with similar symptoms, making it difficult for families to know what steps to take when illness strikesAbbott's Panbio™ COVID-19/Flu A&B Self-Test detects COVID-19, Influenza A and Influenza B from a single nasal swab in approximately 15 minutesMISSISSAUGA, ON, Nov. 10, 2026 /CNW/ -- As respiratory viruses begin circulating across Canada, many families are left wondering what to do when illness strikes at home. To help provide greater clarity, Abbott (NYSE:ABT) today announced availability of its Panbio™ COVID-19/Flu A&B Self-Test, which
- INSIDEREXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- SECSEC Form 10-Q filed by Abbott Laboratories10-Q - ABBOTT LABORATORIES (0000001800) (Filer)
- PRLate-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of strokeLate-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show the device achieved high closure rates of the left atrial appendage (LAA) and a low incidence of strokeAbbott's Amulet 360™ LAA Occluder is a next-generation device designed to reduce the risk of stroke and other serious blood clot-related complications in people with atrial fibrillation not caused by a heart valve issueABBOTT PARK, Ill., Nov. 2, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, announced today one-year results for its investigational Amulet 360™ Left Atrial Ap
- PRAbbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy SystemSonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary arteries and restore blood flowThe system is designed to bring purposeful innovation to treating complex coronary calcium, with longer treatment lengths, more pulses and enhanced catheter deliverabilityApproval of the investigational system would further strengthen Abbott's comprehensive coronary devices portfolio, complementing its advanced imaging, lesion preparation and stent technologiesABBOTT PARK, Ill., Nov. 1, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, announced stron
- PRAbbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve diseaseCROWN-MV trial will evaluate the safety and effectiveness of investigational Cephea mitral valve replacement deviceAbbott's Cephea is designed to provide a new, minimally invasive option for treating mitral valve disease, the most common type of heart valve ailment30-day early feasibility study results for Cephea will be presented at TCT 2026ABBOTT PARK, Ill., Oct. 29, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, announced today it has initiated the CROWN-MV pivotal trial evaluating the safety and effectiveness of its investigational Cephea™ Mitral Valve System in treating people with symptomatic mitral valve disease who are not candidates for surgery and transcathet
- ANALYSTAbbott Labs downgraded by ArgusArgus downgraded Abbott Labs from Buy to Hold
- PRAbbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatmentPowered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of detection below one part per million under high-end inputs 1, 2, 3The next-generation Oncodetect test builds on more than 20 years of trusted leadership in using genomic information to personalize cancer care Modeling estimates more than 3 million U.S. patients with solid tumors could potentially benefit from MRD testing†ABBOTT PARK, Ill., Oct. 26, 2026 /PRNewswire/ -- For many people with cancer, completing treatment can bring a new uncertainty: Is my cancer really gone? Even after treatment, small am
- PRAbbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancerBeta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing1Building on its leadership in colorectal cancer screening with the Cologuard® test, Abbott is connecting innovations across the cancer care continuum, from early detection to post-treatment monitoringABBOTT PARK, Ill., Oct. 23, 2026 /PRNewswire/ -- For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whether minute traces of the disease remain. Abbott (NYSE:ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequ
- PRNasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold FirmVANCOUVER, BC, Oct. 21, 2026 /CNW/ -- Stock Preachers News Commentary - Three sessions into the week, growth and small caps are setting the pace. The Nasdaq Composite jumped 1.04% on the day and is up 2.14% for the week to 26,700.62, while the Russell 2000 added 0.44% to push its weekly gain to 2.36%. The Dow and S&P 500 are contributing too, both up more than 1.2% for the week, as earnings from industrial, healthcare, exchange and homebuilding names give investors fresh data points to sort leaders from laggards. Active Companies from around the markets with current developments this week include: RTX (NYSE:RTX), Abbott (NYSE:ABT), CME Group Inc. (NASDAQ:CME), M/I Homes, Inc. (NYSE:MHO), and
- SECSEC Form 8-K filed by Abbott Laboratories8-K - ABBOTT LABORATORIES (0000001800) (Filer)
- SECSEC Form 8-K filed by Abbott Laboratories8-K - ABBOTT LABORATORIES (0000001800) (Filer)
- PRAbbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS GuidanceThird-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percentThird-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42Expands portfolio with key new product approvalsABBOTT PARK, Ill., Oct. 21, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the third quarter ended Sept. 30, 2026. Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis.Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items.Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent1.Abbott reaffirms the midpoint of previously provide
- PRAbbott announces its intention to separate its global Nutrition business into an independent, publicly traded companySeparation will unlock potential of both companies to pursue distinct growth and value-creation strategiesThe new Nutrition company will be a global leader in the rapidly growing healthy nutrition market, with a portfolio of iconic, category-leading brands, including Similac, PediaSure, Pedialyte, Glucerna and EnsureAbbott will have accelerated sales growth and an expanded margin profileAbbott intends to separate its Nutrition business through a tax-free distribution to Abbott shareholdersSeparation expected to be completed by the end of 2027ABBOTT PARK, Ill., Oct. 21, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, today announced its intention to separate its Nutritio
- PRAbbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoopNew powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support muscle recovery‡* and 3 grams of calcium HMB (beta-hydroxy-beta-methylbutyrate) to help preserve muscleEnsure Max Protein 3-in-1 formula provides muscle support in a single daily serving to support muscle health goals—and is available in chocolate and vanilla at major U.S. retailersMuscle-supporting ingredients like creatine and HMB are moving beyond the gym and into mainstream wellness routines as more adults prioritize strength and fitnessABBOTT PARK, Ill., Oct. 7, 2026 /PRNewswire/ -- Muscle support just got simpler. Abbott (NYSE:ABT) today announced the launch of
- ANALYSTBarclays initiated coverage on Abbott Labs with a new price targetBarclays initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $120.00
- PRAbbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart conditionFor the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF AppRising PAP can signal worsening heart failure weeks before patients experience symptomsNew capabilities help patients take a more active role in their care and stay connected to their care teams between doctor visitsABBOTT PARK, Ill., Oct. 5, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App. For the first time, care
- INSIDERSEC Form 4 filed by Director Stratton John G4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Director Gonzalez Patricia Paola4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Director Conroy Kevin T4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Director Ahuja Nita4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Director Roman Michael F4 - ABBOTT LABORATORIES (0000001800) (Issuer)
ABT rankings
- Other17(43%)
- Insider10(25%)
- Analyst4(10%)
- SEC Filings4(10%)
- Earnings3(8%)
- Dividends2(5%)
Our reporting on ABT
Abbott Laboratories (ABT) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 12 wire items for ABT, including 7 press releases and news items, 2 analyst ratings and 2 SEC filings. The most recent was published Nov 19, 2026.
ABT FAQ
9 questionsWhat does Abbott Laboratories do?
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo...What is ABT revenue?
Abbott Laboratories (ABT) reported $48.23B of revenue for the twelve months ended Sep 30, 2026. That is up 10.0% from the year before. Revenue for fiscal 2025 was $44.33B.Is ABT profitable?
Yes. Abbott Laboratories earned $4.70B in net income for the twelve months ended Sep 30, 2026, a net margin of 9.7%.How much cash and debt does ABT have?
Abbott Laboratories reported $4.05B in cash and cash equivalents and $31.16B of debt on its most recent balance sheet in SEC filings.Where does ABT stock trade?
Abbott Laboratories (ABT) is listed on NYSE.What sector and industry is ABT in?
Abbott Laboratories operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ABT?
Across the last 8 analyst actions on Abbott Laboratories, there were 3 upgrades and 2 downgrades. The most recent action was from Leerink Partners: Outperform with a $124.00 price target on 2026-11-19. Recent price targets range from $92.00 to $145.00.What companies are similar to ABT?
Notable peers in the same industry include BSX (Boston Scientific Corporation), DHR (Danaher Corporation), BLCO (Bausch + Lomb Corporation), MDT (Medtronic plc.), SYK (Stryker Corporation). Compare ABT side-by-side with any of them on Quantisnow.How can I track ABT on Quantisnow?
Quantisnow aggregates Abbott Laboratories's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABT to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change
